Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1–2% of all thyroid
cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC …

Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. In
2017, it was the fifth most common cancer in women. Although the majority of thyroid tumors …

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid
cancer. Since the guidelines for the management of ATC by the American Thyroid …

Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a
poor prognosis and an unmet need for effective treatment, especially for patients without …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Abstract The Japan Associations of Endocrine Surgeons has developed the revised version
of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines …

Background Lenvatinib has been approved by regulatory agencies in Japan, the United
States, and the European Union for treatment of radioiodine-refractory differentiated thyroid …

Anaplastic thyroid cancer (ATC) is an infrequent thyroid tumor that usually occurs in elderly
patients. There is often a history of previous differentiated thyroid cancer suggesting a …